Current Scheduling Status
N/A
Year(s) and type of review / ECDD meetings
Added to surveillance list by 2nd WG meeting (2017)
Drug Class
Recommendation (from TRS)
Information has been brought to WHO’s attention that 5-MAPB is being misused in a number of Member States. 5-MAPB is clandestinely manufactured and has been identified in seized products. 5-MAPB has amphetamine-like effects that include euphoria, increased blood pressure and temperature, decreased appetite, increased wakefulness and physical activity, along with rapid and/or irregular heartbeat. 5-MAPB has been associated with a stimulant intoxication state. To date, 5-MAPB has not been pre- or critically reviewed by the ECDD.